YL064
YL064 is a multi-target STAT3-c-MYC inhibitor that directly binds to ATXN3 and inhibits its deubiquitinating activity, thereby promoting the ubiquitination and proteasomal degradation of oncogenic substrates of ATXN3. YL064 inhibits the phosphorylation of STAT3-Tyr705 without altering the total protein level of STAT3; meanwhile, it directly binds to the SH2 domain of STAT3 to block the dimerization, nuclear translocation, and DNA-binding activity of STAT3. YL064 directly targets the C-terminal HLH-Zip domain of c-Myc, upregulates the phosphorylation of c-Myc at the Thr58 site, and induces the ubiquitination and proteasome-dependent degradation of c-Myc. YL064 suppresses tumor cell proliferation, induces G2/M cell cycle arrest, reduces cell migration and invasion capacities, and triggers cancer cell apoptosis. YL064 can be used in related research on breast cancer, prostate cancer, diffuse large B-cell lymphoma, and multiple myeloma.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 1240580-64-6
- 화학식: C25H27NO4S
- 분자량:437.55
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
제품 설명
|
Stat-3 |
c‑Myc |
ATXN3 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MDA-MB-231 | IC50 |
39.71 μM
|
Antiproliferative activity against Py8119, MCF-7, and MDA-MB-231 breast cancer cells assessed by CCK-8 assay after 24 h incubation.
Antiproliferative activity against Py8119, MCF-7, and MDA-MB-231 breast cancer cells assessed by CCK-8 assay after 24 h incubation.
|
s41419-026-09171-5 |
| PC-3 | IC50 |
44.71 μM
|
Antiproliferative activity against PC-3 human prostate cancer cells assessed by CCK-8 assay after 24 h incubation.
Antiproliferative activity against PC-3 human prostate cancer cells assessed by CCK-8 assay after 24 h incubation.
|
s41419-026-09171-5 |
In Vitro
YL064 (12 μM - gradient concentrations; 15 min) is a potent, concentration-dependent inhibitor of purified recombinant full-length ATXN3 deubiquitinating activity in the cell-free in vitro enzymatic assay[1].
YL064 (100 μM) directly binds to purified full-length recombinant ATXN3 protein in the cell-free thermal shift assay[1].
YL064 (100 μM; 2 h) directly interacts with endogenous ATXN3 in Py8119 mouse breast cancer cells, as confirmed by the cellular thermal shift assay[1].
YL064 exhibits direct physical binding to recombinant full-length ATXN3 protein with a measured KD of 649 μM in the SPR assay[1].
YL064 (24 h) potently inhibits the proliferation of Py8119, MCF-7, and MDA-MB-231 breast cancer cells, with an average IC50 of 39.71 μM following 24 h treatment[1].
YL064 (10-20 μM; 24 h) effectively inhibits STAT3 activation and downstream cyclin D1 and Mcl-1 expression even in U266 human multiple myeloma cells co-cultured with protective HS-5 bone marrow stromal cells[3].
YL064 (10-100 μM; 2 h) directly and selectively binds to STAT3 protein, with competitive displacement confirming specific target interaction[3].
YL064 promotes the post-transcriptional degradation of the ATXN3 substrate KLF4 in Py8119 and MCF-7 breast cancer cells in a dose-dependent manner[1].
YL064 (10 days) significantly suppresses clonogenic survival of MCF-7 and Py8119 breast cancer cells after 10 days of continuous treatment[1].
YL064 (15 μM; overnight incubation, followed by 2 h EdU labeling at 37 °C) suppresses DNA synthesis and cell proliferation in breast cancer cells, as shown by reduced EdU incorporation[1].
YL064 (20 μM; 24 h) potently suppresses both the migratory and invasive capabilities of MCF-7 and MDA-MB-231 breast cancer cells in vitro[1].
YL064 (5-40 μM) reduces YAP protein levels in PC-3 prostate cancer cells in a dose-dependent manner by promoting proteasomal degradation[1].
YL064 (24 h) inhibits the proliferation of PC-3 human prostate cancer cells with an IC50 of 44.71 μM after 24 h of treatment[1].
YL064 (0.1-100 μM; 12-48 h) potently suppresses the viability of OCI-Ly3 and SU-DHL-2 diffuse large B cell lymphoma cells in dose- and time-dependent patterns[2].
YL064 (5-20 μM; 1-12 h) induces dose- and time-dependent reduction of c-Myc protein expression in OCI-Ly3 diffuse large B cell lymphoma cells[2].
YL064 (10 μM; 6 h) triggers proteasome-dependent degradation of c-Myc protein in OCI-Ly3 diffuse large B cell lymphoma cells[2].
YL064 (10 μM; 6 h)-induced c-Myc degradation in OCI-Ly3 diffuse large B cell lymphoma cells occurs independently of the lysosomal degradation pathway[2].
YL064 (25-500 μM) directly interacts with c-Myc protein in OCI-Ly3 diffuse large B cell lymphoma cells, as demonstrated by the dose-dependent reduction in c-Myc thermal stability[2].
YL064 (50 μM; 10×106 excess unlabeled YL064) directly and specifically binds to native c-Myc protein in OCI-Ly3 diffuse large B cell lymphoma cell lysates[2].
YL064 (25-50 μM; 30 min) directly interacts with purified recombinant c-Myc protein in a cell-free in vitro system in a dose-dependent manner[2].
YL064 (Indicated individual concentrations; 48 h) exerts synergistic anti-proliferative effects in combination with ABT-199 in OCI-Ly3 diffuse large B cell lymphoma cells[2].
YL064 (2.5-20 μM; 24 h) selectively inhibits constitutive STAT3 phosphorylation at Tyr705 without affecting Ser727 phosphorylation or total STAT3 protein levels in U266 human multiple myeloma cells[3].
YL064 (20 μM; 0-24 h) causes rapid, near-complete loss of Tyr705 phosphorylated STAT3 within 6 h of treatment in U266 human multiple myeloma cells[3].
YL064 (20 μM; 3-24 h) suppresses expression of the STAT3 downstream pro-survival target proteins cyclin D1 and Mcl-1 in a time-dependent manner in U266 human multiple myeloma cells[3].
YL064 (2.5-20 μM; 6 h) potently blocks IL-6-induced STAT3 Tyr705 phosphorylation in MM1.S human multiple myeloma cells[3].
YL064 (0-100 μM) directly engages STAT3 in intact U266 human multiple myeloma cells, causing dose-dependent thermal destabilization of the target protein[3].
YL064 (20 μM; 24 h) disrupts the dimerization of STAT3 in U266 human multiple myeloma cells[3].
YL064 (2.5-20 μM; 24 h) induces dose-dependent apoptotic cleavage of caspase 3 and PARP-1 in U266 and MM1.S human multiple myeloma cells[3].
YL064 (20 μM; 0-60 min) rapidly suppresses IL-6-induced STAT3 Tyr705 phosphorylation within 1 h of treatment in MM1.S human multiple myeloma cells[3].
YL064 (20 μM; 6 h) blocks IL-6-induced nuclear translocation of STAT3 in MM1.S human multiple myeloma cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:OCI-Ly3 and SU-DHL-2 diffuse large B cell lymphoma cells
-
Concentration:0.1-100 μM
-
Incubation Time:12 h, 24 h, 48 h
-
Result:Reduced the viability of OCI-Ly3 and SU-DHL-2 DLBCL cells in a clear dose-dependent and time-dependent manner.
-
Cell Line:OCI-Ly3 diffuse large B cell lymphoma cells
-
Concentration:5, 10, 20 μM (12 h incubation); 10 μM (1, 3, 6, 9, 12 h incubation)
-
Incubation Time:12 h (5, 10, 20 μM); 1, 3, 6, 9, 12 h (10 μM)
-
Result:Markedly reduced c-Myc protein levels in OCI-Ly3 cells in a strict dose-dependent manner when applied for 12 h, and also in a time-dependent manner at the fixed 10 μM concentration. c-Myc protein abundance progressively decreased as YL064 concentration increased, and similarly decreased as treatment duration was extended to 12 h.
-
Cell Line:OCI-Ly3 diffuse large B cell lymphoma cells
-
Concentration:10 μM
-
Incubation Time:6 h
-
Result:Strongly reduced c-Myc protein levels in OCI-Ly3 cells.
Co-treatment with proteasome inhibitor blocked this YL064-induced c-Myc degradation, restoring high levels of c-Myc protein in treated cells.\nInduced substantial reduction of c-Myc protein levels.
The lysosome inhibitor did not prevent this YL064-mediated c-Myc degradation, as c-Myc protein levels remained significantly suppressed in the combined treatment group.
-
Cell Line:OCI-Ly3 diffuse large B cell lymphoma cells
-
Concentration:Indicated individual concentrations of YL064
-
Incubation Time:48 h
-
Result:Combined with ABT-199 produced a strongly synergistic reduction in OCI-Ly3 cell viability, with greater growth inhibition than either single agent treatment.
-
Cell Line:Human multiple myeloma U266 and MM1.S cell lines
-
Concentration:2.5, 5, 10, 20 μM
-
Incubation Time:24 h
-
Result:Induced dose-dependent apoptosis in both U266 and MM1.S cells, with clear appearance of cleaved caspase 3 and cleaved PARP-1 observed starting at 10 μM, and more robust cleavage detected at 20 μM.
Decreased full-length caspase 3 and full-length PARP-1 levels correspondingly with increasing concentration.
-
Cell Line:Human U266 multiple myeloma cells
-
Concentration:2.5, 5, 10, 20 μM
-
Incubation Time:24 h
-
Result:Decreased the level of phosphorylated STAT3 (Tyr705) in a dose-dependent manner, with near-complete abrogation of p-STAT3 (Tyr705) observed at 20 μM.
Did not alter levels of phosphorylated STAT3 at Ser727 across all tested concentrations, and left total STAT3 protein levels unchanged.
-
Cell Line:Human U266 multiple myeloma cells
-
Concentration:20 μM
-
Incubation Time:3, 6, 12, 24 h
-
Result:Completely abrogated the phosphorylation of STAT3 at Tyr705 as early as 6 h after treatment.
Caused phosphorylation of STAT3 at Ser727 to gradually increase slightly over the 24 h treatment period, and total STAT3 protein levels to decrease progressively with longer incubation time.\nTime-dependently reduced the protein levels of both cyclin D1 and Mcl-1.
Substantially diminished cyclin D1 protein levels after 3 h of treatment, and rendered them almost undetectable by 24 h.
Caused Mcl-1 protein levels to decrease progressively across all tested time points, with clear reduction evident as early as 3 h post-treatment.
-
Cell Line:IL-6-stimulated human MM1.S multiple myeloma cells
-
Concentration:2.5, 5, 10, 20 μM
-
Incubation Time:6 h
-
Result:Dose-dependently inhibited IL-6-induced STAT3 phosphorylation at Tyr705.
Produced strong inhibition of p-STAT3 (Tyr705) at 5 μM, and achieved full suppression of IL-6-triggered Tyr705 phosphorylation at 20 μM.
Left total STAT3 protein levels relatively consistent across all treatment groups.
-
Cell Line:IL-6-stimulated human MM1.S multiple myeloma cells
-
Concentration:20 μM
-
Incubation Time:0, 5, 10, 20, 30, 60 min pre-incubation before IL-6 stimulation
-
Result:Progressively inhibited the IL-6-induced phosphorylation of STAT3 at Tyr705 with increasing pre-incubation time.
Caused significant reduction in p-STAT3 (Tyr705) after 20 min of pretreatment, and near-complete inhibition of phosphorylation at 60 min post-treatment.
-
Cell Line:IL-6-stimulated human MM1.S multiple myeloma cells
-
Concentration:20 μM
-
Incubation Time:6 h pre-incubation before IL-6 stimulation
-
Result:Completely blocked IL-6-triggered nuclear translocation of STAT3, with STAT3 retained in the cytoplasm and no nuclear co-localization with DAPI observed.
-
Cell Line:Human U266 multiple myeloma cells, and U266 cells co-cultured with HS-5 human bone marrow stromal cells
-
Concentration:10, 20 μM
-
Incubation Time:24 h
-
Result:Dose-dependently reduced p-STAT3 (Tyr705), cyclin D1, and Mcl-1 levels in monocultured U266 cells, with near-complete loss of all three proteins at 20 μM.
Still reduced p-STAT3 (Tyr705), cyclin D1, and Mcl-1 levels in a dose-dependent manner in U266 cells co-cultured with HS-5 stromal cells, with substantial suppression observed at 20 μM.
-
Cell Line:Human U266 multiple myeloma cells
-
Concentration:20 μM FITC-YL064
-
Incubation Time:8 h
-
Result:Generated strong green fluorescent signal from FITC-YL064 that extensively overlapped with the red STAT3 immunofluorescence signal across the cytoplasm of U266 cells, producing a merged orange/yellow fluorescent signal that demonstrated clear intracellular colocalization of YL064 and STAT3.
In Vivo
YL064 (30 mg/kg; i.p.; daily; 9 days) significantly suppresses human multiple myeloma xenograft tumor growth in mice with minimal impact on body weight, concomitant with STAT3 pathway inhibition and induction of tumor cell apoptosis[3].
YL064 (30 mg/kg) exerts in vivo anti-lymphoma efficacy in OCI-Ly3 DEL xenograft mice via c-Myc downregulation, reduced tumor cell proliferation, and enhanced tumor cell apoptosis[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J mice (around 6 to 8 weeks old)[1]
-
Dosage:20 mg/kg
-
Administration:i.p.; alternate days; 6 treatments
-
Result:Exerted significant in vivo anti-tumor effects in an orthotopic murine breast cancer model, reducing tumor growth, KLF4 protein levels, and tumor cell proliferation.
-
Animal Model:BALB/c nu/nu nude mice (Female, aged 4-6 weeks)[3]
-
Dosage:30 mg/kg
-
Administration:i.p.; daily; 9 days
-
Result:Reduced the tumor burden of MM1.S tumor-bearing mice.
Did not produce notable changes in the body weight of mice.
Decreased expression of proliferating cell nuclear antigen (PCNA) in tumor tissues.
Reduced levels of phosphorylated STAT3 (Tyr705) in tumor tissues.
Suppressed expression of the downstream STAT3 target gene product cyclin D1 in tumor tissues.
Altered TUNEL staining indicative of increased apoptotic cell death within the tumor.
Chemical Information
-
CAS No. 1240580-64-6
-
분자량 437.55
-
화학식 C25H27NO4S
-
SMILES
CC(C=C1)=CC=C1S[C@@H]2C(C=CC(O)=C3O)=C3[C@@]4(CC(C(OC)=C5)=O)[C@]5([H])[C@@H]2N(CC4)C
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocol
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
Somatic Cell Culture
A method of simulating the in vivo environment in vitro to maintain the cell growth, differentation and main functions.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cytoplasmic-Nuclear Fractionated Protein Extraction
Cytoplasmic-nuclear fractionated protein extraction separates soluble cytoplasmic proteins from nuclear-enriched proteins by mild plasma-membrane permeabilization, differential centrifugation, washing of nuclei, and extraction of nuclear proteins for downstream immunoblotting or related molecular analysis. The readout is the relative abundance of a protein in cytoplasmic and nuclear fractions, commonly assessed by western blotting together with compartment markers such as tubulin or pyruvate kinase for cytoplasm and lamin, nucleoporin, hnRNP, H2AX, or Lamin B for nuclear fractions.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Chemotaxis Gradient Chamber Assay 1
The chemotaxis gradient chamber assay is based on the principle of observing directional cell migration in response to a stable, linear or quasi-linear concentration gradient of a chemoattractant formed between two fluid reservoirs separated by a narrow observation chamber. Cells placed within the chamber respond to the gradient by polarized movement toward higher chemoattractant concentrations, allowing quantification of chemotactic behavior in real time under microscopy. The classic Zigmond chamber design enables simultaneous visualization of gradient formation and individual cell trajectories, making it suitable for studying leukocyte chemotaxis and other motile cell types in vitro.
-
Under-Agarose Cell Migration Assay
The under-agarose cell migration assay is a classical in vitro chemotaxis method designed to evaluate directed cell movement through a semi-solid agarose matrix toward soluble chemoattractant gradients, enabling visualization and quantification of leukocyte or motile cell migration in a confined 2D-like environment. In this system, cells and chemoattractants are placed in separate wells cut into an agarose gel, allowing diffusion-driven gradient formation that guides directional migration, which is typically assessed by measuring migration distance, cell morphology changes, and accumulation toward the chemoattractant source. This assay has been widely used to study neutrophil and leukocyte chemotaxis as a simple alternative to filter-based migration systems and allows direct microscopic observation of migrating cells under near-physiological confinement conditions.
-
Transwell/Boyden Chamber Migration Assay
The Transwell/Boyden chamber migration assay measures cell movement through a porous membrane separating an upper and lower chamber, usually after a chemoattractant gradient is established by placing cells in the upper chamber and chemoattractant-containing medium in the lower chamber. The readout is generated by quantifying cells that traverse the membrane and appear on the lower membrane surface or in the lower chamber, depending on whether the cell type is adherent or non-adherent. This assay reflects chemotactic or haptotactic migration rather than matrix invasion unless an extracellular-matrix barrier is added to the membrane.
-
Protein Extraction
Protein extraction uses physical, chemical or biological methods, such as ultrasonic disruption, salting out, cell lysis, electrophoresis, etc., to destroy the cell membrane structure and to separate the proteins from different components according to their characteristics.
-
3D Collagen/Hydrogel Matrix Migration Assay
The 3D collagen/hydrogel matrix migration assay is based on embedding cells within or on top of a fibrillar collagen type I-rich three-dimensional matrix to model in vivo-like extracellular matrix (ECM) architecture, enabling analysis of cell migration through a physically and biochemically relevant scaffold. In contrast to 2D migration systems, cells in 3D matrices interact with fibrillar collagen networks, requiring coordinated adhesion remodeling and proteolytic or non-proteolytic deformation mechanisms to move through confined spaces, thereby providing a more physiologically relevant readout of invasive and migratory behavior in tissue-like environments. Cell movement in 3D collagen matrices is typically quantified by tracking single-cell trajectories, invasion depth, or matrix penetration over time, reflecting combined effects of cytoskeletal dynamics, cell-ECM adhesion turnover, and ECM remodeling. These systems are widely used to study tumor cell invasion and stromal cell motili
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Cell invasion
Cell invasion is the ability of cells to migrate from one area to another via the extracellular matrix. Cell invasion is the response of normal and cancer cells to chemical and mechanical stimuli. Before migrating to a new region, the extracellular matrix is degraded by proteases within the cell. Cell invasion often occurs during wound repair, vascularization and inflammation, abnormal tissue invasion, and tumor cell metastasis.
-
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
-
Cell-Exclusion Zone Migration Assay
The Cell-Exclusion Zone (CEZ) migration assay is an in vitro 2D cell migration method in which a defined cell-free area is created using removable physical barriers such as silicone stoppers, allowing cells to be seeded around the barrier and subsequently migrate into the cleared zone after barrier removal. This approach enables quantification of collective cell migration by monitoring repopulation of the initially cell-free region over time using microscopy-based imaging. Compared with scratch-based wound healing assays, barrier-based exclusion methods are designed to avoid mechanical damage to the extracellular matrix and reduce injury-induced effects on boundary cells, thereby improving interpretability of migration behavior in vitro. The assay readout is typically the progressive reduction in the cell-free area or the number of cells invading the exclusion zone, reflecting coordinated cell motility relevant to physiological processes such as wound healing, epithelial repair, and ca
-
Chemotaxis Gradient Chamber Assay 2
Chemotaxis gradient chamber assays measure directional cell migration in response to a soluble chemical gradient by imaging cells as they move across a defined observation region; the readout is generated from time-lapse cell trajectories, displacement toward the gradient, forward migration index, trajectory plots, rose/polar plots, and statistical tests of non-random directionality. The Dunn chamber is a direct-viewing glass chamber in which cells migrate across a bridge between control and chemoattractant wells, allowing observation of cells in a linear concentration gradient; related direct-viewing formats include the Insall chamber, which supports defined unidirectional gradients and high numerical-aperture microscopy, and the μ-Slide Chemotaxis chamber, which supports long-term live-cell imaging and gradient characterization with fluorescent dye.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Scratch/Wound-Healing Migration Assay
The scratch/wound-healing migration assay measures collective migration of adherent cells into an experimentally created cell-free gap in a confluent monolayer. The readout is generated by imaging the gap immediately after scratching and at later time points, then quantifying reduction in wound area, wound width, or percentage closure as cells move into the denuded region. Gap closure reflects cell migration but may also include cell proliferation, so interpretation should distinguish migration-focused conditions from proliferation-driven closure when possible, such as by using short assay windows, serum-controlled conditions, cell counting, or proliferation controls reported in published protocols.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Neural Crest/Neuronal Cell Migration Explant Assay
Neural crest (NC) and neuronal cell migration explant assays are in vitro systems in which neural tube-derived tissues are cultured to allow premigratory or newly emigrated neural crest cells to undergo epithelial-to-mesenchymal transition (EMT), migrate away from the explant, and form a measurable radial outgrowth that reflects migratory capacity and environmental responsiveness. These assays typically quantify migration by measuring the expansion of cell outgrowth from neural tube or neural plate border explants over time, often comparing early and later timepoints to derive a migration index such as a radius ratio, which reflects net cell dispersal from the explant core. Neural tube explant cultures preserve key aspects of neural crest behavior, including EMT, migration, and early differentiation, making them suitable for assessing intrinsic migratory ability and extrinsic cue dependence. However, studies emphasize that migratory outgrowth from neural tube explants may include non-n
-
CFSE Dye Dilution Proliferation Assay
The CFSE (carboxyfluorescein diacetate succinimidyl ester) dye dilution proliferation assay is based on the covalent labeling of intracellular proteins by a cell-permeant fluorescent dye that becomes fluorescent upon intracellular ester cleavage and then is stably retained within cells. As labeled cells divide, the dye is partitioned equally between daughter cells, resulting in a stepwise halving of fluorescence intensity that can be quantified by flow cytometry to determine the number of cell divisions undergone by each cell population. This fluorescence dilution approach enables quantitative tracking of lymphocyte proliferation at the single-cell level over multiple rounds of division. CFSE-based proliferation analysis has been widely applied to measure antigen-driven lymphocyte expansion in vitro, where discrete fluorescence peaks correspond to successive cell divisions and allow reconstruction of proliferative history within heterogeneous populations.
-
Dye-dilution cell tracking and proliferation staining
Dye-dilution cell tracking assays quantify cell proliferation by covalently labeling intracellular proteins with a stable fluorescent dye that is equally partitioned between daughter cells during mitosis, resulting in stepwise halving of fluorescence intensity with each cell division as measured by flow cytometry histograms. Carboxyfluorescein diacetate succinimidyl ester (CFSE) is a prototypical dye that diffuses into cells, is enzymatically converted into a fluorescent compound, and then covalently binds intracellular amine groups, producing long-lived fluorescence suitable for tracking multiple rounds of division in vitro and in vivo. Successive generations of dividing cells form discrete peaks of decreasing fluorescence intensity, enabling estimation of proliferation history, precursor frequency, and division index within heterogeneous populations. Alternative dyes such as CellTrace Violet (CTV) and far-red membrane dyes (e. g. , PKH26) follow the same dilution principle but differ
-
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Cell Counting-Based Growth Curve Assay
Cell counting-based growth curve assays quantify cell proliferation by directly measuring changes in viable cell number over time using manual or automated counting methods such as hemocytometer-based counting or instrument-assisted cell enumeration, enabling construction of growth curves that reflect population expansion dynamics in response to culture conditions. A widely used approach is trypan blue exclusion with hemocytometer counting, where membrane-compromised (non-viable) cells take up the dye, allowing discrimination between viable and non-viable cells while simultaneously enabling total cell number quantification. Repeated sampling across time points allows estimation of proliferation rate, growth phases, and comparative growth kinetics between experimental conditions.
-
Colony Formation (Clonogenic) Assay
The clonogenic (colony formation) assay measures the ability of a single cell to retain reproductive viability and form a macroscopic colony, typically defined as a cluster derived from one progenitor cell after a defined growth period. This assay is widely used to evaluate cell survival after exposure to ionizing radiation or cytotoxic treatments and is considered a standard method in radiation biology for generating dose-response relationships of reproductive cell death. Colony formation reflects long-term proliferative capacity rather than short-term metabolic activity, and survival is quantified by comparing treated versus untreated conditions based on colony number and derived survival fractions.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
-
Ki-67 Immunostaining Proliferation Assay
Ki-67 immunostaining measures the growth fraction of a cell population by detecting Ki-67, a nuclear antigen present in proliferating cells and absent in quiescent G0 cells. The readout is the percentage of Ki-67-positive nuclei among total counted cells, commonly called the Ki-67 labeling index or proliferation index.
-
PCNA Immunodetection Proliferation Assay
PCNA immunodetection measures proliferative activity by detecting proliferating cell nuclear antigen, a nuclear protein associated with DNA polymerase δ function and DNA replication. The assay readout is the proportion of PCNA-positive nuclei among total counted cells, but PCNA labeling is not identical to BrdU labeling because PCNA can mark late G1/early S-associated replication competence and may persist beyond active DNA synthesis depending on fixation and extraction conditions.
-
Protocol for Cell Counting and Cell Density Analysis
Cell counting and cell-density analysis estimate the number of cells in a known volume or field area. Manual hemocytometer counting uses a chamber of defined geometry to convert counted cells into cells/mL, while automated counters and image-analysis workflows detect cell objects from optical, brightfield, fluorescence, impedance, or digital-image features. Trypan blue viability counting is based on dye exclusion: viable cells with intact membranes exclude dye, while non-viable cells with compromised membranes stain blue. The readout is total cell density, viable-cell density, dead-cell density, and percent viability. Cell density can also be estimated from microscopy images by counting objects per image area, from flow cytometry using calibrated volume or reference particles, or from in situ microscopy in bioreactors after calibration against reference methods such as hemocytometer or flow cytometry.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- YL064
- 1240580-64-6
- YL 064
- YL-064
- STAT
- c-Myc
- Small Interfering RNA (siRNA)
- Apoptosis
- ATXN3
- MDA-MB-231 breast cancer cells
- c-MYC
- STAT3
- MCF-7 breast cancer cells
- PC-3 prostate cancer cells
- Py8119 mouse breast cancer cells
- U266 human multiple myeloma cells
- OCI-Ly3 diffuse large B cell lymphoma cells
- MM1.S human multiple myeloma cells
- Inhibitor
- inhibitor
- inhibit